Physician profile
Pratikkumar J Patel
NPI 1356789200
$2,788.74
in general payments reported to CMS, 2019-2025
23 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.05 · 2020: $84.60 · 2021: $141 · 2022: $145 · 2023: $832 · 2024: $749 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $684.84 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $474.58 | 2019-2025 | Lifevest |
| Amgen INC. | $333.91 | 2023-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $197.60 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $146.78 | 2020-2025 | Varithena Administration Pack, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.57 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $115.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $113.70 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $110.45 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Pfizer INC. | $81.52 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $60.45 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $48.72 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $43.86 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $40.71 | 2023-2025 | Amvuttra, Onpattro |
| Impulse Dynamics (USA) INC. | $26.86 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $25.52 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Esperion Therapeutics, INC. | $23.10 | 2024 | Nexletol |
| Ionis Pharmaceuticals, INC. | $22.43 | 2025 | Tryngolza |
| Bayer Healthcare Pharmaceuticals INC. | $22.36 | 2025 | |
| Cvrx, INC. | $20.94 | 2024 | Barostim Neo System |
| Cardiovascular Systems INC. | $19.89 | 2020 | |
| Lantheus Medical Imaging, INC. | $19.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.04 | 2023 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratikkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.